HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53.

Clicks: 421
ID: 64953
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #3 of 43 articles by views in Neuro-Oncology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Diffuse midline glioma (DMG) is a pediatric malignancy with poor prognosis. Most children die less than one year after diagnosis. Recently, mutations in histone H3 have been identified and are believed to be oncogenic drivers. Targeting this epigenetic abnormality using HDAC inhibitors such as panobinostat (PS) is therefore a novel therapeutic option currently evaluated in clinical trials.BH3 profiling revealed engagement in an irreversible apoptotic process of glioma cells exposed to PS confirmed by Annexin-V/PI staining. Using proteomic analysis of three DMG cell lines we identified two proteins deregulated after PS treatment. We investigated biological effects of their downregulation by silencing RNA but also combinatory effects with PS treatment in vitro and in vivo using a chick embryo DMG model. Electron microscopy was used to validate protein localization.Scaffolding proteins EBP50 and IRSp53 were upregulated by PS treatment. Reduction of these proteins in DMG cell lines leads to blockade of proliferation and migration, invasion and to an increase of apoptosis. EBP50 was found to be expressed in cytoplasm and nucleus in DMG cells, confirming known oncogenic locations of the protein. Treatment of glioma cells with PS together with genetic or chemical inhibition of EBP50 leads to more effective reduction of cell growth in vitro and in vivo.Our data reveal a specific relation between HDACi and scaffolding protein deregulation which might have a potential for therapeutic intervention for cancer treatment.
Reference Key
capdevielle2019hdacneurooncology Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Capdevielle, Caroline;Desplat, Angélique;Charpentier, Justine;Saggliocco, Francis;Thiebaud, Pierre;Thézé, Nadine;Fédou, Sandrine;Hooks, Katarzyna B;Silvestri, Romano;Guyonnet-Duperat, Veronique;Pretel, Mélina;Raymond, Anne-Aurélie;Dupuy, Jean-William;Grosset, Christophe F;Hagedorn, Martin;
Journal Neuro-Oncology
Year 2019
DOI
noz215
URL
Keywords
diffuse midline glioma ebp50 hdaci irsp53 chick chorioallantoic membrane

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.